1-4 of 4
Takeshi Yuasa
Close
Sort by
Journal Articles

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

Shinya Kimura, Haruna Naito, Hidekazu Segawa, Junya Kuroda, Takeshi Yuasa, Kiyoshi Sato, Asumi Yokota, Yuri Kamitsuji, Eri Kawata, Eishi Ashihara, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Kimio Nasu, Tetsuo Asaki, Tomoko Niwa, Kazuko Hirabayashi, Taira Maekawa
Journal: Blood
Blood (2005) 106 (12): 3948–3954.
https://doi.org/10.1182/blood-2005-06-2209
Published: 2005
Journal Articles

Zoledronate Inhibits Leukemia Growth in Bone Marrow and Synergizes with Imatinib Mesylate Against Ph + Primary Leukemic Cells.

Hidekazu Segawa, Shinya Kimura, MD, Junya Kuroda, MD, Takeshi Yuasa, MD, Taira Maekawa, MD
Journal: Blood
Blood (2004) 104 (11): 2096.
https://doi.org/10.1182/blood.V104.11.2096.2096
Published: 2004
Journal Articles

Cancer Immunotherapy: Cytotoxic Activity of γδ T-Cells Expanded Ex Vivo by the Third Generation Bisphosphonate Zoledronate.

Kiyoshi Sato, Shinya Kimura, MD, Takeshi Yuasa, MD, Hiromi Wada, MD, Taira Maekawa, MD
Journal: Blood
Blood (2004) 104 (11): 1347.
https://doi.org/10.1182/blood.V104.11.1347.1347
Published: 2004
Journal Articles

CNS-9, a Novel Specific Inhibitor of ABL Tyrosine Kinase Overcomes Resistance Mechanism of Imatinib.

Shinya Kimura, MD, Hidekazu Segawa, Junya Kuroda, MD, Takeshi Yuasa, MD, Taira Maekawa, MD
Journal: Blood
Blood (2004) 104 (11): 761.
https://doi.org/10.1182/blood.V104.11.761.761
Published: 2004